Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShuai SuBXBin XuWZWen Zheng

Discussion

Loading...

Member takes

Overview

Non-intensive chemotherapy improved response rates in newly diagnosed AML and MDS, indicating effective treatment options.

Key Points

  • To explore the efficacy and safety of selinexor-based non-intensive chemotherapy in newly diagnosed AML or MDS patients.
  • Patients enrolled who refused or were ineligible for intensive chemotherapy received selinexor and azacitidine.
  • Venetoclax dosages were administered during treatment, with follow-ups through weekly bone marrow punctures.
  • Treatment adjustments were made based on patient responses after the first and second weeks.
  • 58.6% of patients achieved complete remission or incomplete remission after the first week.
  • 68.9% of patients achieved complete remission after the second week.
  • 75.9% of patients survived with a median follow-up of 60 days.

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3bfhttps://doi.org/10.1182/blood-2025-1673
View Full Paper
Ask AI
Bookmark
Share